Castle Biosciences reports Q1 adjusted EPS (20c), consensus (7c)

Reports Q1 revenue $87.99M, consensus $80.38M. “We are pleased with the exceptional start to the year, marked by continued growth in test report volume and revenue in the first quarter,” said Derek Maetzold, president and chief executive officer of Castle Biosciences (CSTL). “We believe our ongoing success reflects both the high clinical value that our clinicians receive from our tests coupled with consistent execution and teamwork across our therapeutic areas.”